CERT
Certara, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services · US
$10.96
+0.84%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$11.08
From 52W high−5.26%
Volume827813.00
Market cap$1.67B
P/E (TTM)—
P/S (TTM)4.1x
Div yield—
Key dataNov 4, 2026
Open
$11.08
From 52W high
−5.26%
Volume
827813.00
Market cap
$1.67B
ValuationView details →
P/E (Fwd)
27.9x
EV/EBITDA
17.5x
P/E (TTM)
—
RSI (14)
63.0
MomentumView details →
1D Return
+0.84%
YTD Return
+23.72%
SummaryUpdated Jun 1, 2026
Certara, Inc. (NASDAQ:CERT) is a biosimulation software and services company founded in 2008 and headquartered in Princeton, New Jersey. The company went public in December 2020 and has grown through strategic acquisitions to become a leading provider of model-informed drug development solutions. Certara serves over 2,400 life sciences companies, academic institutions, and government organizations across 19 countries, helping pharmaceutical and biotechnology companies accelerate drug discovery and development through advanced computational modeling and simulation technologies.
Similar companies
Latest newsMore news →
Certara announced that it will release its third-quarter 2026 financial results before market open on November 5, 2026, and hold a conference call at 8:30 a.m. ET.9d agoCertara appointed Julien Perrier as Chief Commercial Officer.92d agoLeif E. Pedersen will transition to Senior Advisor of Certara, Inc. effective August 1, 2026, and will depart the company on December 31, 2026, receiving severance benefits under his existing employment agreement and the company's Executive Officer Severance Policy.93d ago